|
ACTIVATIONS
GASTROINTESTINAL
A022104/NRG-GI010: The Janus Rectal Cancer Trial, NCI version date October 21, 2022, is open to new patient enrollment, effective November 9, 2022 (posted on CTSU).
OTHER PROTOCOL NOTICES
1. ALL DISEASE SITES
NRG-GY022: Actively Recruiting MALE Patients only. Read More
2. BREAST / GASTROINTESTINAL
NRG-BR003, NRG-BR007, NRG-GI004, NRG-GI005, and NRG-GI008: Memo - Scheduling Protocol Therapy for Non-medical Delays (posted to individual protocol pages on the CTSU website)
3. CANCER PREVENTION & CONTROL
NRG-CC005/FORTE: November edition of the FORTE newsletter (posted on CTSU)
4. GASTROINTESTINAL
NRG-GI008: Slides from the Protocol Overview Webinars held on November 1st and 3rd are now posted on CTSU.
5. GENITOURINARY
NRG-GU007: Attention sites with NRG-GU007 open, we are currently enrolling to Dose Level 3, the final dose level for the phase I portion of the trial. More than ever, we need your support in reaching Dose Level 3 target accrual goal to complete the dose finding component of this trial and allow us to progress to the randomized phase II component. Please help us meet this target! Protocol documents for this trial are available on CTSU and please share our NRG-GU007 patient brochure with any eligible patients. Questions regarding this trial can be directed to the study Project Manager, Erin Moye at moyee@nrgoncology.org.
6. GYNECOLOGIC
GOG-0210: Biospecimens, biomarker data, clinical data, and epidemiologic data are available for request. Please visit the NRG Oncology website for more information on this important study with the overall goal of improving the outcome and/or quality of life for patients with endometrial cancer.
GOG-0225: To provide the most accurate and reliable assessment possible, sites are asked to answer any outstanding queries and update the Overall Survival status and last contact date for all patients enrolled on GOG-0225 no later than Friday, December 2, 2022. This trial utilizes the SEDES EDC system for form entry. If site personnel need access to SEDES for this study, please contact support@nrgoncology.org. SEDES can be accessed via the GOG Web menu.
NRG-GY012 and NRG-GY023 – BLOOD PRESSURE CUFF SUPPLY IS VERY LIMITED - Please be advised that VWR has a very limited supply of blood pressure cuffs at present. Please check your supplies on site for any overlooked cuffs prior to ordering. Thank you for your cooperation.
7. LUNG
REGISTER TODAY! Information Webinar for the NRG-LU006 Clinical Trial
NRG Oncology will be hosting an informational webinar regarding the NRG-LU006 clinical trial on Thursday, November 17, 2022, from 7-8 pm ET. This webinar is open to all who register. This webinar is specifically aimed to engage thoracic surgeons and will address surgical concerns, barriers to enrollment and answer protocol-specific questions.
The Phase III randomized NRG-LU006 study is currently active and enrolling patients with malignant pleural mesothelioma (MPM). The trial is designed to compare adjuvant hemithoracic intensity-modulated pleural radiation therapy (IMPRINT) combined with pleurectomy/decortication surgery and systemic therapy to surgery and systemic therapy alone. The goal of this study is to see if the addition of adjuvant hemithoracic IMPRINT can improve overall survival for patients with MPM.
The webinar will be led by Andreas Rimner, MD, the Director of Thoracic Radiation Oncology Research at Memorial Sloan Cancer Kettering Center and NRG-LU006 Principal Investigator. Presentations will be followed by a question and answer segment with the study team.
Register here: https://bit.ly/NRG-LU006-Webinar-Registration
8. VTOC TRAINING
The VTOC Webinar Training Series schedule and registration is available for NRG Oncology Research Associates working on RTOG 0924, RTOG 0920, NRG-HN001, NRG-HN002, NRG-CC003, NRG-CC005 and NRG/SWOG S1914. Space is limited so register now and reserve your seat. The next webinar training is scheduled for Wednesday, December 14, 2022
| 
